Ischemia and ailing function of the myocardium are key factors in the prognosis after myocardial infarction (MI). Angiotensin converting enzyme (ACE) inhibitors have a beneficial effect on severe heart failure inasmuch as mortality is reduced and left ventricular function is improved.12 Animal experimental studies have shown that ACE inhibitors have an advantageous effect on the remodeling of the myocardium after MI.3, 4 Furthermore, clinical studies have demonstrated that captopril prevents progressive dilation of the left ventricle after MI. [5] [6] [7] Experimental studies have also indicated that ACE inhibitors dilate the coronary arteries in cases of acute ischemia. 8, 9 In addition, it has been shown that infarct extension can be impeded and survival improved as a result of ACE inhibition during experimental MI. [9] [10] [11] [12] The effects of ACE inhibitors on the myocardium appear to be multifactorial and promising with regard to an anti-ischemic effect as well as in the treatment of acute heart failure. The present study was designed to elucidate the role played by the ACE inhibitor captopril in combating ischemia of the myocardium and the ability of captopril to improve physical performance in patients having signs of left ventricular dysfunction during the early phase after MI.
Methods

Patient Selection
Patients younger than 70 years of age suffering from MI were included provided that they had left ventricular ejection fraction (EF) <45% as evaluated by echocardiography on day 5 after the MI. The diagnosis of MI was established using the World Health Organization criteria.13 Patients who had previously received treatment for heart failure and who required an ACE inhibitor or digoxin were excluded from the investigation. Furthermore, patients presenting with ECG signs of a previous MI, persistent ST segment deviation, and paradoxical wall movement of the left ventricle demonstrated by echocardiography were also excluded, as were patients with systolic blood pressure < 100 mm Hg, atrial fibrillation, diseases of the heart valves, bundle branch block, severe systemic disease, and liver or kidney disease. Patients who were subjected to coronary artery bypass grafting during the follow-up period were excluded. The reason for this was that this procedure presumably has an effect on the ischemia during the remainder of the follow-up period.14 A total of 64 patients were enrolled; this was the result of background screening of 134 consecutive MI patients. All period. Thus, from day 90, there was a significant difference between the groups (p<0.01) as well as at day 180 (p<0.001), as shown in Table 3 . The same pattern could be seen with regard to exercise-triggered ST depression inasmuch as the captopril group, compared with the placebo group, demonstrated a significantly lower number of patients with ST segment depression during the exercise test (p<0.01) at the end of the study ( Table 4 .
The systolic blood pressure rose in the placebo group from 111±2 mm Hg at baseline to 128±3 mm Hg at the completion of the study (p<0.01). In the captopril group, the systolic blood pressure remained unchanged at 112±2 mm Hg without any reflectory increase in heart rate being observed ( Table 5) .
The working capacity after 30 days was almost identical in the groups, as can be seen in Figure 1 . Expressed as endurance, the average working capacity in the captopril group increased from 540±47 seconds to 738±41 seconds (p<0.01), whereas the placebo group showed a slight but insignificant fall in working capacity from 596±43 seconds to 530±43 seconds. At the end of the study, there was a significant between-group difference in favor of captopril (p<0.01). In Figure 2 . There was no correlation between left ventricular volumes and working capacity in the two groups during the same period.
In the captopril group, the need for adjuvant diuretic therapy was reduced. At the time of randomization, 34% of the patients in this group required diuretic therapy; this was reduced to 10% by the time the study was completed (p<0.05). The need of furosemide in the placebo group remained unchanged: 34% versus 28% (NS).
Concomitant anti-ischemic therapy remained, on the whole, unchanged during the study period. At day 180, metoprolol was given to 21 patients in both groups, and diltiazem was given to four captopril-treated patients versus seven patients given placebo. The use of isosorbide mononitrate was of the same order of magnitude during the whole of the study period. The number of cardiac-related events comprising death, reinfarction, or coronary artery bypass graft (CABG) were also in favor of captopril treatment. A total of nine such events (one cardiac death, two CABGs, and six reinfarctions) occurred in the placebo group versus only two (one cardiac death and one CABG) in the captopril group (p<0.05). Side effects leading to a reduction in dosage of the study drug were seen in three patients in the captopril group. These were cough in one and slight dizziness in two.
Discussion Patients having suffered a recent MI are exposed to progressive deterioration in or new manifestations of their coronary disease. Therapy of such patients must take several pathological processes into consideration, of which residual ischemia and left ventricular dysfunction are probably the most important. To date, no single medical treatment has had a positive effect on both factors. Therefore, the object of the present investigation was to determine whether ACE inhibitor intervention has a role in the treatment of these conditions after MI.
The patient material was selected in such a manner that all of the MI patients had left ventricular dysfunction. We observed16 (as did Pfeffer et al and Sharp et al5-7) a progressive dilation of the left ventricle in patients given placebo. Although no significant between-group difference in EDVI was observed (probably because of the short observation period), this aspect of the remodeling process was prevented in patients treated with captopril. Furthermore, the systolic volume was reduced, leading to an increased stroke volume, indicating an improved contractility and improved systolic function of the left ventricle.
Myocardial ischemia is the result of an imbalance between the oxygen requirement and the supply. As a result of a reduction in the reserve capacity of vasodilation as well as extrinsic compression during the systole combined with an overall higher metabolic rate, the subendocardium is more prone to ischemia than the subepicardium. Therefore, high metabolic demand and/or maldistribution of the transmural flow are responsible for subendocardial ischemia with subsequent ST segment depression.17 '18 This can be detected by exercise testing and ambulatory ECG monitoring, both of which have a high sensitivity in patients with known coronary artery disease, and can be used for evaluation of the effect of treatment as well as prognosis in post-MI patients. [19] [20] [21] [22] ST segment depression (symptomatic and asymptomatic) is relatively frequent during the first days after MI and is observed in 35-82% of patients.23-25 These ST segment depressions within or outside the infarct zone may reflect ischemic episodes indicating stenosis of the coronary arteries or infarct extension after reocclusion. 26 We were not particularly interested in the ischemic changes within the infarct zone itself but only in the residual ischemia in the noninfarcted myocardium. ECG mapping was therefore carried out so that leads showing infarct-related ST segment changes and/or Q waves could be avoided. To enhance the sensitivity of ambulatory ECG monitoring, two separate leads were placed in the area that was presumably unaffected by the infarction. The same procedure was used during exercise testing.
The ambulatory ST segment depression, evaluated as the average duration of the spontaneous ST depression as well as the number of patients with ST depression, was of the same order of magnitude in both groups at baseline. The frequency of ischemia (67%) in our studies was relatively high although within the limits that have been reported earlier,23-25 a factor that can be explained by the selection criteria (e.g., left ventricular dysfunction). We observed a significant fall in the duration of ambulatory ischemia in both groups within the first month. The ambulatory ischemia was further reduced in the group treated with captopril in contrast to the placebo group, giving rise to a significant difference after 3 months. As no major changes were made in the adjuvant anti-ischemic treatment, this effect must be ascribed to captopril. ACE inhibitors interfere with the formation of angiotensin II, a vasoconstrictor of both systemic and coronary arteries.27 The effect on the coronary circulation has been shown in experimental studies in which ACE inhibition produced a reduction in infarct size explained by increased coronary perfusion, especially of the ischemic area.8 9 The effect on the peripheral circulation causes a reduction in both afterload and preload and thus decreases the myocardial work load. This produces a lessening of the myocardial oxygen demand as well as a fall in blood pressure without a reflectory increase in heart rate, leading to reduced myocardial oxygen consumption.9,28 We did not observe a direct blood pressure-lowering effect of captopril, but the expected rise in blood pressure caused by increased stroke volume as seen in the placebo group was prevented. This could be mediated via an increase in arterial compliance.29 There are a number of mechanisms by which ACE inhibitors influence the myocardial oxygen requirement and supply via their hemodynamic effects.
It appears that the process of myocardial remodeling also contributes to the myocardial oxygen demand inasmuch as we were able to demonstrate a positive correlation between the changes in left ventricular EDVI and duration of ambulatory ST segment depressions from day 30 to day 180. The process of remodeling comprises dilation of the infarcted segment and hypertrophy of the noninfarcted segment,30 both of which lead to increased myocardial oxygen demand via increased myocardial work load.31 Therefore, the fact that patients given placebo developed progressive dilation of the left ventricle can explain why we observed a deterioration in the ambulatory ischemic burden as well as in the exercise-triggered ischemia in this group after the temporary improvement in the early stages after MI. The fact that we observed the effects of captopril treatment gradually over the study period is in agreement with the assumption that the tissue renin-angiotensin system regulates long-term organ function in contrast to the short-term effect of the circulating renin-angiotensin system. 32 The improvement in working capacity was also in favor of captopril treatment, and this, too, was observed as a gradual improvement. It has been shown that this effect on exercise capacity is correlated to the configuration of the left ventricle. 33 We have been unable to demonstrate this correlation in our study, perhaps because of an asynchronism in the phases of development. However, from our observations, we are able to conclude that as both of these effects are influenced by the treatment, factors other than these such as peripheral hemodynamic changes must also be present. The beneficial effect of captopril on myocardial ischemia and dysfunction after MI is also reflected in clinical improvement inasmuch as the occurrence of cardiacrelated events was significantly lower in the captopril group, based on the frequency of reinfarctions. Results from the SAVE trial confirm this protective effect of captopril with a 25% reduction in number of reinfarcts and a cardiovascular mortality reduction of 21%.34 The reason for this difference could be the beneficial effect on the myocardial oxygen requirement and supply. In addition, captopril has been shown to inhibit platelet aggregation and thereby reduce the release of vasoconstrictors (thromboxane A2) and stimulators of smooth muscle proliferation (platelet-derived growth factor). 35 The area of vascular remodeling, antiatherosclerotic effects, and effects on platelet function and fibrinolytic activity of ACE inhibitors require further elucidation. The need for adjuvant diuretic treatment in the captopril group was significantly reduced; this effect is presumably mediated via an improvement in the function of the left ventricle and/or via a reduction in ischemiainduced dysfunction.
Conclusions
Treatment with captopril of patients with dysfunction of the left ventricle after MI appears advantageous inasmuch as captopril has a positive effect on myocardial ischemia, left ventricular function, and physical performance.
